AUS
NZ
UK
CA
USA
IND
Highlights:
Faron Pharmaceuticals is seeking partnerships to fund phase III development of its cancer drug, bexmarilimab.
Promising data from the BEXMAB trial shows a 79% response rate in treating relapsed and refractory myelodysplastic syndrome (MDS).
The company has renewed its Scientific Advisory Board, bringing on leading cancer experts to enhance its clinical pipeline.
Faron Pharmaceuticals Limited (LSE:FARN) is actively seeking partnerships to fund the phase III development and commercialization of its innovative cancer treatment, bexmarilimab. This move follows a successful fundraising round that secured €30.7 million in June. The company is currently in discussions with several potential partners but has not finalized any agreements, opting to evaluate all terms meticulously to ensure optimal outcomes for both the company and its shareholders.
Faron has reiterated its commitment to maintaining flexibility throughout these discussions, suggesting that it may further strengthen its financial position before making any final decisions. This approach aims to create a more robust foundation for the company as it navigates the complexities of partnership agreements.
Ahead of its Capital Markets Day, which is scheduled for later Tuesday, Faron provided updates on its clinical pipeline, showcasing significant progress. A key highlight was the promising data from the BEXMAB phase I/II trial, which focuses on treating relapsed and refractory myelodysplastic syndrome (MDS). The trial has demonstrated a remarkable 79% response rate, significantly surpassing typical outcomes for similar treatments. Additionally, patients involved in the trial have shown extended survival times compared to standard care.
These positive results, along with ongoing recruitment efforts for the phase II trial, position bexmarilimab as a potential game-changer in the realm of cancer immunotherapy. CEO Dr. Juho Jalkanen stated, "As previously communicated, everything is progressing as planned and our focus is to ensure that we are armed with adequate resources to meet our objectives of completing phase II of the BEXMAB trial and optimizing the outcome of partnering with phase II data." He emphasized that the next strategic business decision will be pivotal in determining how the value and future of bexmarilimab are allocated.
Dr. Jalkanen also acknowledged the extensive work that has gone into developing bexmarilimab over the past two decades, emphasizing the importance of maximizing its potential for both patients and stakeholders.
In addition to the clinical updates, Faron has renewed its Scientific Advisory Board, welcoming top international cancer experts to bolster its research and development efforts as it aims to advance bexmarilimab’s potential.
